10 completed, 5 recruiting, 3 unknown, 1 active not recruiting. 20 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 10, Recruiting 5, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 3 | 4 | Recruiting 3, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension Midodrine Oral Tablet - Heart Failure With Reduced Ejection Fraction, Hypotension | Phase 2 / Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 56 | 2026-08-07 | 2026-09-08 |
| Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients Lumacaftor 200 MG, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 2 | Recruiting | Qanatpharma AG | 60 | 2026-07-01 | 2026-07-17 |
| Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy GDMT - Heart Failure With Reduced Ejection Fraction, Heart Rhythm Disorder | Phase 2 / Phase 3 | Recruiting | Herlev and Gentofte Hospital | 348 | 2025-01-09 | 2026-02-23 |
| Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure Vsling - Heart Failure With Reduced Ejection Fraction | Phase 2 | Recruiting | Cardiac Success | 20 | 2024-11-15 | 2026-10-28 |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Semaglutide Injectable Product, Calorie-restricted diet - Heart Failure With Reduced Ejection Fraction, Obesity | Phase 2 / Phase 3 | Recruiting | Jens D Hove, MD,PHD | 100 | 2024-04-30 | 2026-06-23 |
| Study of JK07 in Patients With Chronic Heart Failure JK07, Placebo - Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 282 | 2024-03-28 | 2026-05-22 |
| Ketones in Heart Failure With Reduced Ejection Fraction ketone ester, placebo - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Duke University | 25 | 2024-03-06 | 2026-09-03 |
| Heart Failure Polypill at a Safety Net Hospital Heart failure polypill, Control Rx - Heart Failure With Reduced Ejection Fraction, HIV Infections | Phase 2 | Completed | University of California, San Francisco | 35 | 2024-02-27 | 2025-12-31 |
| A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) Tovinontrine (CRD-750), Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Cardurion Pharmaceuticals, Inc. | 557 | 2024-02-13 | 2026-09-01 |
| Phase Ib/IIa Trial With AC01 in Patients With HFrEF AC01, Placebo Minitablets - Heart Failure With Reduced Ejection Fraction | Phase 1 / Phase 2 | Completed | AnaCardio AB | 58 | 2023-02-23 | 2026-05-07 |
| " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD - Congenital Heart Disease, Heart Failure | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cardiologia Ignacio Chavez | 160 | 2023-02-06 | 2022-11-02 |
| Effectiveness of CRD-740 in Heart Failure CRD-740, Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 2 | Terminated | Cardurion Pharmaceuticals, Inc. | 60 | 2022-05-26 | 2024-12-19 |
| Safety of HMA-CD20 in Patients With HFrEF Rituximab - Heart Failure With Reduced Ejection Fraction | Phase 2 | Unknown | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud | 10 | 2021-01-01 | 2020-08-05 |
| EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot Evolocumab - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Fundació Institut Germans Trias i Pujol | 46 | 2018-12-03 | 2023-02-15 |
| Effect of Melatonin on Cardiovascular and Muscle Mass and Function in Patients With Heart Failure Melatonin 10 mg, Placebo Oral Tablet - Heart Failure With Reduced Ejection Fraction | Phase 2 | Unknown | Isfahan University of Medical Sciences | 90 | 2018-11-30 | 2019-03-28 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 MYK-491, Placebo - Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 52 | 2018-02-06 | 2023-02-02 |
| Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction Empagliflozin 10 MG, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Morten Schou | 190 | 2017-06-29 | 2020-02-05 |
| Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction 25 mg Omecamtiv Mecarbil, Placebo, 37.5 mg Omecamtiv Mecarbil - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Cytokinetics | 81 | 2016-04-14 | 2021-07-27 |
| VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients Equilia® Vagal Nerve Stimulation - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | LivaNova | 15 | 2014-10-07 | 2018-03-13 |
| Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients LCZ696 - Heart Failure With Reduced Ejection Fraction | Phase 2 | Completed | Novartis Pharmaceuticals | 498 | 2013-11-01 | 2015-10-15 |
Heart Failure (10) · Cardiovascular Diseases (2) · Heart Diseases (2) · Atrial Fibrillation (1) · Atrial Flutter (1) · Cardiomyopathy, Dilated (1) · Cognitive Dysfunction (1) · Fibromatosis, Gingival, 2 (1) · HIV Infections (1) · Heart Defects, Congenital (1) · Heart Failure, Diastolic (1) · Heart Failure, Systolic (1) · Hypotension (1) · Ketosis (1) · Medication Adherence (1)
Cardiovascular Diseases (9) · Heart Diseases (9) · Pathological Conditions, Signs and Symptoms (3) · Behavior (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Nutritional and Metabolic Diseases (2) · Signs and Symptoms (2) · Acid-Base Imbalance (1) · Acidosis (1) · Arrhythmias, Cardiac (1) · Atrophy (1) · Blood-Borne Infections (1) · Body Weight (1) · Body Weight Changes (1) · Cardiomegaly (1)
empagliflozin (2) · sacubitril and valsartan sodium hydrate drug combination (2) · BID protein, human (1) · Caloric Restriction (1) · Melatonin (1) · Midodrine (1) · Rituximab (1) · Tin Fluorides (1) · Valsartan (1) · evolocumab (1) · formic acid 4-(3-oxobutyl)phenyl ester (1) · lumacaftor (1) · omecamtiv mecarbil (1) · sacubitril (1)
Cardurion Pharmaceuticals, Inc. (2) · AnaCardio AB (1) · Bristol-Myers Squibb (1) · Cardiac Success (1) · Cytokinetics (1) · Duke University (1) · Fundació Institut Germans Trias i Pujol (1) · Herlev and Gentofte Hospital (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud (1) · Isfahan University of Medical Sciences (1) · Jens D Hove, MD,PHD (1) · LivaNova (1) · Morten Schou (1) · Novartis Pharmaceuticals (1)
United States (7) · Canada (5) · United Kingdom (5) · Denmark (3) · Germany (3) · Italy (3) · Netherlands (3) · Spain (3) · Belgium (2) · Bulgaria (2) · France (2) · Hungary (2) · Israel (2) · Poland (2) · Puerto Rico (2)
Albert Hagege, MD, PhD (1) · Carlos Guizar-Sanchez, MD (1) · Colette DeJong, MD (1) · Edgar Garcia-Cruz, MD (1) · Emil Wolsk, MD (1) · Gail Berman (1) · Gian Jimenez-Rodriguez, MD (1) · Howard Surks, MD (1) · Ian Paterson, MD (1) · Jacob E Moller, MD (1) · Jens D Hove (1) · Kim Connelly (1) · Lars H Lund, MD PhD (1)
PMID 27170530, PMID 29164797, PMID 30520545, PMID 30918029, PMID 31227014, PMID 32865377, PMID 33186500, PMID 33357505, PMID 33404637, PMID 33447845, PMID 33832352, PMID 34061581, PMID 34509409, PMID 34743533, PMID 35219331, PMID 35973031, PMID 39843293, PMID 40118491, PMID 40502611, PMID 41171251, PMID 41711194, PMID 42341796
2017 (2), 2023 (2), K23HL161348 (1)